#United States #National Harbor #Genprex #TUSC2 #Meharry Medical

Genprex Unveils Exciting Research on TUSC2 at GSA 2026

Genprex, Inc., a pioneering clinical-stage biotechnology firm, is making waves in the realm of gene therapy research. The company is set to present vital findings regarding the TUSC2 gene, part of its leading oncology treatment, Reqorsa, during the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting. This event will be held between November 4-7, 2026, in National Harbor, Maryland.

The focus of this research is the TUSC2 gene, which is critical for restoring tumor-suppressor functions in cancer treatment as well as insulin-producing capabilities in diabetes management. In this case, specific attention is being given to TUSC2's role in mitochondrial biology and the cellular aging process. This research indicates exciting possibilities beyond traditional oncology applications of Reqorsa, paving the way for further scientific exploration in the aging spectrum.

Collaboration with Meharry Medical College

Genprex's collaboration with Meharry Medical College, initiated in 2024, serves as a thriving research fellowship that investigates various aspects of the REQORSA platform. This partnership seeks to unravel the complexities around mitochondrial metabolism, molecular aging, and their relationships to cancer.

With the mounting focus on longevity and the science of aging, this endeavor is a stepping stone to a deeper understanding of how TUSC2 functions may influence not just tumor suppression but overall cell health, resilience, and longevity.

Ryan Confer, the CEO of Genprex, expressed enthusiasm regarding this collaboration. He noted, “Understanding the broader potential of TUSC2 in biological processes beyond cancer is exciting. This research could unveil opportunities that welcome further exploration within scientific communities.”

Details of the Presentation

The presentation will include a poster titled “TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program.” This will be displayed as part of the Late-Breaking Poster Session on November 4, 2026. Presenting this groundbreaking research will be Dr. Mark S. Berger, the Chief Medical Officer of Genprex, who is set to discuss the findings and their implications.

What Lies Ahead for REQORSA

As Genprex progresses its research, the company is steadfast in its mission to not only develop treatment for lung cancer but also explore the potential intersection of gene therapies with other medical domains such as diabetes and aging. Although comprehensive studies are still required to confirm these findings, Genprex’s ongoing research could redefine the scope of gene therapies and their extensive applications.

In closing, with its eyes set firmly on the horizon, Genprex is not merely advancing gene therapy for cancer but is ambitiously extending its research umbrella across age-related processes, steadily working to provide innovative solutions for patients with significant unmet medical needs. Their participation and presentation at the GSA conference exemplify this commitment to pioneering therapeutics that may change the face of medicine.

To stay updated on their findings, researchers and interested parties are encouraged to check Genprex’s website for accessible information following the presentation period, adhering to relevant conference disclosure policies.

For those intrigued by the intersections of gene therapy and aging, Genprex's continuing exploration in this notable field may yield promising avenues for future therapeutic investigations.